Navigation Links
Researchers decode workings of mysterious, but critical TB drug
Date:8/11/2011

For nearly 60 years, Pyrazinamide (PZA) has been used in conjunction with other medications to treat tuberculosis (TB), but scientists did not fully understand how the drug killed TB bacteria. PZA plays a unique role in shortening the duration of current TB therapy to six months and is used frequently to treat multi-drug resistant TB. A new study, led by researchers at the Johns Hopkins Bloomberg School of Public Health, suggests that PZA binds to a specific protein named RpsA and inhibits trans-translation, a process that enables the TB bacteria to survive under stressful conditions. Their findings, published in the August 11, 2011 edition of Science Express, could lead to new targets for developing more effective anti-TB drugs.

"PZA is a peculiar and unconventional drug that works very differently from common antibiotics that mainly kill growing bacteria. PZA primarily kills non-growing bacteria called persisters that are not susceptible to common antibiotics," said Ying Zhang, MD, PhD, senior author of the study and professor in the Bloomberg School's W. Harry Feinstone Department of Molecular Microbiology and Immunology. "While PZA works very well in the body against TB, it has no effect on the growing bacteria in a test tube, which has made it difficult to understand just how it works."

PZA is converted to the active form of pyrazinoic acid (POA) by an amidase enzyme (PncA) also identified by Zhang's group in 1996. Through a series of experiments, Zhang and his colleagues determined that POA binds to ribosomal protein S1 (RpsA), a vital protein in the trans-translation process. Trans-translation is essential for cell survival under stress conditions. Partially synthesized proteins which are produced under stress conditions are toxic to the bacterial cell. It has developed a mechanism called trans-translation to add a short peptide tag to the partially produced toxic proteins so they can be recognized for degradation by proteases to relieve the toxicity. Inhibition of trans-translation by PZA explains why the drug can eradicate persisting organisms, and thereby shortening the therapy.

"There is renewed interest in PZA because it is the only drug that cannot be replaced among the current TB drugs without compromising the efficacy of therapy. The identification of the drug target RpsA not only offers a new resistance mechanism to PZA but also opens up a way for designing a new generation of antibiotics that target persister bacteria for improved treatment of chronic and persistent infections including TB," said Zhang.


'/>"/>

Contact: Natalie Wood-Wright
nwoodwri@jhsph.edu
410-614-6029
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related biology news :

1. Researchers fight cholera with computer forecasting
2. Vanderbilt researchers, international team, uncover genes linked to multiple sclerosis
3. Narcissism may benefit the young, researchers report; but older adults? Not so much
4. York U researchers zero in on protein that may help treat obesity, diabetes
5. Researchers use human cells to engineer functional anal sphincters in lab
6. Researchers use neutrons to spy on the elusive hydronium ion
7. UGA researchers study threats to white sturgeon
8. Researchers gain new insights into how tumor cells are fed
9. University of Virginia researchers uncover new catalysis site
10. U of Minnesota researchers discover a natural food preservative that kills food-borne bacteria
11. Researchers develop fully cooked food-aid product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
Breaking Biology Technology: